These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26308222)

  • 1. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V; Patel H; Kurlander JL; Essoi B; Yang J; Mahableshwarkar AR; Samp JC; Akhras KS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J; Joish V
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
    Zhu L; Ferries E; Suthoff E; Namjoshi M; Bera R
    J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
    [No Abstract]   [Full Text] [Related]  

  • 9. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
    Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
    J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
    [No Abstract]   [Full Text] [Related]  

  • 11. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of treatment-resistant depression on health care utilization and costs.
    Crown WH; Finkelstein S; Berndt ER; Ling D; Poret AW; Rush AJ; Russell JM
    J Clin Psychiatry; 2002 Nov; 63(11):963-71. PubMed ID: 12444808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.
    Shrestha SS; Zhang P; Li R; Thompson TJ; Chapman DP; Barker L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):102-10. PubMed ID: 23490596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants.
    Duan Y; Wei J; Geng W; Jiang J; Zhao X; Li T; Jiang Y; Shi L; Cao J; Zhu G; Zhang K; Yu X
    J Affect Disord; 2019 Sep; 256():1-7. PubMed ID: 31154087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.